Haojie Chen

Haojie Chen

Auto-generated profile, based on publicly available information

Haojie Chen

Department of Urology, School of Medicine, Xin-Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2022 in The Prostate
Verified
Journal Article
Closed access
PDF file
JZJiatong Zhou
Jiatong Zhou
HCHaojie Chen
Haojie Chen
YWYanyuan Wu
Yanyuan Wu
BSBowen Shi
Bowen Shi
JDJie Ding
Jie Ding
JQJun Qi
Jun Qi

24 February 2022 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
HCHaojie Chen
Haojie Chen
BSBowen Shi
Bowen Shi
YWYanyuan Wu
Yanyuan Wu
YQYuhang Qian
Yuhang Qian
JZJiatong Zhou
Jiatong Zhou
YYYu Yongjiang
Yu Yongjiang

23 December 2021 in Cell Proliferation
Verified
Journal Article
Open access
PDF file
BSBowen Shi
Bowen Shi
YWYanyuan Wu
Yanyuan Wu
HCHaojie Chen
Haojie Chen
JDJie Ding
Jie Ding
JQJun Qi
Jun Qi
Objectives: To elaborately decipher the mouse and human bladders at single‐cell levels.Materials and Methods: We collected more than 50,000 cells from multiple datasets and created, up to date, the largest integrated bladder datasets. Pseudotime trajectory of urothelium and interstitial cells, as well as dynamic cell‐cell interactions, was investigated. Biological activity scores and different roles of signaling pathways between certain cell clusters were also identified.Results: The glucose score was significantly high in most urothelial cells, while the score of H3 acetylation was roughly equally distributed across all cell types. Several genes via a pseudotime pattern in mouse (Car3, Dkk2, Tnc, etc.) and human (FBLN1, S100A10, etc.) were discovered. S100A6, TMSB4X, and typical uroplakin genes seemed as shared pseudotime genes for urothelial cells in both human and mouse datasets. In combinational mouse (n = 16,688) and human (n = 22,080) bladders, we verified 1,330 and 1,449 interactive ligand‐receptor pairs, respectively. The distinct incoming and outgoing signaling was significantly associated with specific cell types. Collagen was the strongest signal from fibroblasts to urothelial basal cells in mouse, while laminin pathway for urothelial basal cells to smooth muscle cells (SMCs) in human. Fibronectin 1 pathway was intensely sent by myofibroblasts, received by urothelial cells, and almost exclusively mediated by SMCs in mouse bladder. Interestingly, the cell cluster of SMCs 2 was the dominant sender and mediator for Notch signaling in the human bladder, while SMCs 1 was not. The expression of integrin superfamily (the most common communicative pairs) was depicted, and their co‐expression patterns were located in certain cell types (eg, Itgb1 and Itgb4 in mouse and human basal cells).Conclusions: This study provides a complete interpretation of the normal bladder at single‐cell levels, offering an in‐depth resource and foundation for future research.

3 May 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
HCHaojie Chen
Haojie Chen
JLJia Luo
Jia Luo
SCShaojun Chen
Shaojun Chen
BSBowen Shi
Bowen Shi
XZXiaocui Zheng
Xiaocui Zheng
YYYu Yongjiang
Yu Yongjiang
Drug resistance is responsible for castration-resistant prostate cancer (CRPC)-associated mortality. While ATP binding cassette subfamily C member 5 (ABCC5) has been reported to regulate multiple drug resistance, its drug-efflux function may not be the main reason underlying resistance to enzalutamide, an androgen receptor inhibitor. Here, we aimed to determine whether the non-drug efflux function of ABCC5 affects enzalutamide resistance. The ABCC5 expression data in patients with prostate cancer (PCa) were retrieved from The Cancer Genome Atlas and Gene Expression Omnibus, and their correlation with disease prognosis was analyzed. Immunohistochemical staining was performed on a cohort of 80 patient samples. Proliferation of enzalutamide-resistant 22RV1 and C4-2B cells was investigated using CCK-8, EdU, and colony formation assays. The effect of ABCC5 silencing on enzalutamide resensitization was evaluated in vitro and in vivo. Functional assays indicated that ABCC5 depletion resensitized enzalutamide-resistant cells to inhibit cell growth and impeded xenograft tumor proliferation. Mechanistically, luciferase and ChIP assays confirmed that P65 regulated AR expression and activity by binding to its promoter, while ABCC5-mediated resistance effected by AR-V7 (one of the widely studied AR splicing variants that meditate AR antagonist resistance) upregulation could be reversed by P65 knockdown. Furthermore, activation of the NF-κB pathway reversed the effects of ABCC5 knockdown by extra AR-V7 expression. Thus, ABCC5 might be a novel target for enzalutamide-resistant CRPC treatment.

23 August 2025 in Biomarker Research
Verified
Journal Article
Open access
PDF file
FJFu-Hao Ji
Fu-Hao Ji
YQYu-Hang Qian
Yu-Hang Qian
XGXiu-Chen Guo
Xiu-Chen Guo
HLHai-Hong Liao
Hai-Hong Liao
JHJia-Cheng Huang
Jia-Cheng Huang
LWLin Wang
Lin Wang
The androgen receptor signaling inhibitor enzalutamide (Enz) is one the primary therapeutic drugs for advanced prostate cancer (PCa). Nevertheless, most of patients ultimately develop resistance to Enz. Through an integrated analysis of CRISPR genome-wide and kinome-wide screens, coupled with observations of elevated expression levels in Enz-resistant cell lines and PCa tumor tissues, our study identified RPS6KC1 as a novel essential gene implicated in Enz resistance. Mechanistically, our research indicates that the Warburg effect induces H3K18 lactylation, which regulates the expression of RPS6KC1 via the transcription factor P65. Elevated expression of RPS6KC1 was found to recruit PRDX3 to the mitochondria, thereby mitigating ferroptosis. These findings suggest that the H3K18la/NF-κB/RPS6KC1/PRDX3 axis is important for the development of resistance to Enz. Our results suggest that the combination of Enz with targeted RPS6KC1 inhibition or a ferroptosis inducer may represent a promising therapeutic strategy to overcome Enz resistance. Graphical Abstract